• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Healthcare·MNTC.ST
Share

Mentice AB Stocks

SEK 16.7Last Updated 19.10.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

SEK 48.54M

SEK 16.7
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Mentice AB (publ), founded in 1998 and headquartered in Gothenburg, Sweden, specializes in delivering advanced endovascular simulation solutions. These are utilized by educational institutions, healthcare systems, and medical device manufacturers globally, with the company's operations spanning across Europe, the Middle East, Africa, the Asia Pacific region, and the Americas. Its business is structured across distinct segments focusing on the Medical Device Industry, Healthcare Systems, and Strategic Alliances. The company offers a comprehensive suite of software modules designed for training in a wide array of interventional procedures. These include acute ischemic stroke, atrial septal defect/patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee, carotid, and renal interventions, along with patient-specific simulations. The portfolio further encompasses advanced and essential coronary procedures, intermediate coronary, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic and uterine artery embolization, radiation safety, transarterial chemoembolization, transseptal puncture, vascular trauma, and cardiac rhythm management. Additionally, Mentice provides crucial support for interventionalists transitioning from transfemoral to transradial access techniques. Beyond software, Mentice's product line features sophisticated medical simulators for endovascular therapies, accompanied by compatible accessories and extensions. They also supply specialized silicone vasculature, as well as cardiac, vascular, and neurovascular flow systems. Innovative digital offerings include the Mentice Right Heart Cath App, a mobile tool for interactive exploration of right heart catheterization procedures, and the Mentice Live Learning Center, which facilitates remote learning through its VIST G endovascular simulation platform. All these comprehensive solutions are engineered to educate, train, and significantly enhance the skills of medical professionals.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA, trading

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of MNTC.ST is 22.6 and suggests 35.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.10.2026 03:02

SpaceX and Tesla Are Discussing a Merger — Musk

21.10.2026 01:11

SpaceX's profit more than doubled expectations. The annual revenue target is $1 trillion.

21.10.2026 00:45

The Wells Fargo indicator has issued a buy signal for the first time in nearly 1.5 years

20.10.2026 23:27

AI giants are pushing for data center savings. Who stands to lose?

20.10.2026 22:32

DeepSeek open-sources tool to help cut AI operating costs

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026